Certara executives detailed a strategic realignment around two growth engines, ACE and MID3, at the Jefferies 2026 Global Healthcare Conference. The company is embedding AI into products and internal operations while pursuing about $10 million in cost reductions. CEO Jon Resnick, who started on Jan. 1, said the mission is to transform clinical trials. The realignment aims to simplify operations and sharpen go-to-market execution.
Tap to vote and see what everyone thinks.
Inside Apple's Secret AI Meeting
Summary by ByteBrief